一分钟看懂
这是一项关于乳腺癌的I 期研究，登记的药物或干预包括BGB-21447；Fulvestrant；BGB-43395，当前状态为招募中。登记地点显示中国广州、郑州、上海、天津等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BGB-21447；Fulvestrant；BGB-43395 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) · 广州
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Fudan University Shanghai Cancer Centerpudong · 上海
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · 杭州
公开的入选条件
- * Histologically or cytologically confirmed HR+/HER2- metastatic breast cancer. Part 1A and 1B: Participants must have received ≥ 1 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the
- * Female participants will be required (either continue ongoing or initiate as soon as feasible) to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.
- * Male participants may be required to use GnRH agonists when being treated with fulvestrant at the discretion of the investigator.
- * Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
- * Adequate organ function.
- * Female participants of childbearing potential and nonsterile male participants with female partners of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for 7 days after the last dose o
- * Food effect substudy only: Participants who are able and willing to fast overnight (≥ 10 hours) and consume a high-fat meal.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06756932；登记信息更新于 2026-09-14。